Zentiva Pharma GmbH Sustainability Profile
Zentiva Pharma GmbH, a prominent player in the pharmaceutical industry, is headquartered in Germany and operates extensively across Europe. Founded in 2003, Zentiva has established itself as a leader in the development and distribution of generic and specialty medicines, focusing on high-quality, affordable healthcare solutions. The company’s core offerings include a diverse range of prescription medications, over-the-counter products, and biosimilars, all designed to meet the evolving needs of patients and healthcare providers. Zentiva's commitment to quality and innovation has positioned it as a trusted name in the market, with notable achievements in expanding access to essential medicines. With a strong emphasis on sustainability and patient-centric approaches, Zentiva continues to enhance its market presence, striving to improve health outcomes across its operational regions.
DitchCarbon Score
How does Zentiva Pharma GmbH's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Zentiva Pharma GmbH's score of 37 is higher than 58% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Zentiva Pharma GmbH, headquartered in Germany, currently does not have specific carbon emissions data available for the most recent year. The company is a current subsidiary of Zentiva Group, a.s., from which it inherits emissions data and climate commitments. As of now, there are no documented reduction targets or climate pledges specific to Zentiva Pharma GmbH. Zentiva Group, a.s. has established various climate initiatives, but specific details regarding emissions reductions or targets have not been disclosed for Zentiva Pharma GmbH. The absence of emissions data and reduction initiatives suggests that the company may still be in the early stages of formalising its climate strategy. In the context of the pharmaceutical industry, companies are increasingly focusing on sustainability and carbon footprint reduction. Zentiva Pharma GmbH's commitment to climate action may evolve as it aligns with the broader goals of its parent company, Zentiva Group, a.s.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2024 | |
|---|---|---|
| Scope 1 | 305,480,000 | 0,000,000 |
| Scope 2 | 79,081,000 | 0,000,000 |
| Scope 3 | - | 00,000,000 |
How Carbon Intensive is Zentiva Pharma GmbH's Industry?
How Carbon Intensive is Zentiva Pharma GmbH's Location?
Zentiva Pharma GmbH's Scope 3 Categories Breakdown
The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 86% of Scope 3 emissions.
Top Scope 3 Categories
Zentiva Pharma GmbH's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Zentiva Pharma GmbH has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
